Form 4 Filing for Atara Biotherapeutics, Inc.

Yanina Grant-Huerta, Chief Accounting Officer of Atara Biotherapeutics, Inc., reported a sale of 2,414 shares of Common Stock on May 18, 2026. The shares were sold at an average price of $9.1286 per share, with prices ranging from $9.12 to $9.40. This sale was conducted automatically to cover tax withholding obligations related to the vesting of previously granted restricted stock units, as per a sale-to-cover provision in the award agreement. Following this transaction, Ms. Grant-Huerta owns 49,636 shares of Common Stock. The filing details are based on Form 4 and the provided transaction data.